Neoclarityn (Desloratadine)

Desloratadine acts on the histamine H1‑receptor pathway to control allergic disease manifestations.

• Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge.
• Chronic idiopathic urticaria: alleviates hives and associated itching.
• Seasonal hay fever: provides symptomatic relief of nasal and ocular allergy symptoms.

• Desloratadine selectively blocks peripheral H1‑histamine receptors, preventing histamine from binding and triggering the cascade that leads to vasodilation, increased vascular permeability, and sensory nerve stimulation. By inhibiting this receptor activity, it reduces the classic signs of allergic inflammation without significant central nervous system penetration.

Desloratadine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate head discomfort.
• Dry mouth: reduced salivary flow causing throat dryness.
• Fatigue: feeling of tiredness or reduced energy.
• Nausea: occasional stomach upset.
• Drowsiness (rare): mild sedation in sensitive individuals.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips or throat requiring urgent care.
• Severe rash or Stevens‑Johnson syndrome: extensive skin involvement.
• Anaphylaxis: rapid onset of allergic reaction with breathing difficulty.
• Cardiac arrhythmia: irregular heartbeat reported in isolated cases.

Desloratadine should be used with awareness of specific safety considerations.

• Pregnancy: consult a healthcare professional before use; data are limited.
• Breastfeeding: consider potential exposure to the infant via milk.
• Hepatic impairment: dose adjustment may be required in severe liver disease.
• Renal impairment: monitor patients with reduced kidney function.
• Driving and machinery: avoid operating heavy equipment if drowsiness occurs.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Desloratadine may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Ketoconazole: strong CYP3A4 inhibition can increase desloratadine levels.
• Erythromycin: may raise plasma concentrations, raising risk of side effects.
• Ritonavir: potent CYP3A4 inhibitor, can lead to excessive exposure.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance sedation in susceptible individuals.
• Other antihistamines: additive antihistaminic effect may increase drowsiness.
• Theophylline: possible increase in plasma theophylline levels.